Strathspey Crown acquired Evolus, giving its subsidiary Alphaeon Corporation the exclusive license to market the neurotoxin developed by Daewoon Pharmaceutical.
Breaking News
Strathspey Crown acquired Evolus, giving its subsidiary Alphaeon Corporation the exclusive license to market the neurotoxin developed by Daewoon Pharmaceutical.